Pfizer Corporation

Lifecore Biomedical, Inc.

W James Huang

Timothy Michael Lukas

Jonathan Richard Lillis

Kevin Richard Back

Aidan James Harper

Michael Cram

Sumit Luthra

Richard L Kronenthal

Douglas B Johns

The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.

Formulations of a PI3K/mTOR-inhibitor for intravenous administration

The present invention relates to a pharmaceutical aqueous formulation comprising -(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.

Formulations of a PI3K/mTor-inhibitor for intravenous administration

A method of reducing post-operative adhesion formation by topically applying an ionically crosslinked carboxyl-containing polysaccharide or a pharmacologically acceptable salt thereof, e.g. sodium hyaluronate crosslinked with ferric chloride, to a site of surgical trauma.

Ionically crosslinked carboxyl-containing polysaccharides for adhesion

Growing community of inventors

New York, NY, United States of America

W James Huang